Jun 11, 2026 – 6.12pmBlackstone is coming into the second half hot. The global buyout firm wants to scale up sector tearaway Nucleus Network, its $1 billion clinical trials business that’s making close to $70 million earnings, with the acquisition of ASX-listed Healius’ Agilex Biolabs.People with knowledge of the deal, who requested anonymity, told Street Talk that Blackstone’s local outpost was preparing to bid for Agilex, which has been put up for sale by ASX-listed Healius and is slated to fetch a pricetag of as much as $200 million.Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
Blackstone seeks to bolster $1b clinical trials biz with Agilex buy
Bioanalytical laboratories are highly strategic and there are only three of note in Australia, including Genesis Capital-owned Crux Biolabs.
182 words~1 min read
